Beta-2 Microglobulin, Urine
Beta-2 Microglobulin (β2-M) is a small globular peptide with a molecular weight of 11,800 D. It is identical to the light chain of the major histocompatibility complex (MHC) antigen (HLA) 5. Its tertiary structure is homologous to the CH3-IgG immunoglobulin domain. Thus β2-M is present on the surface of all nucleated cells with the exception of trophoblast. It also occurs in all body fluids. Its biological function has not been confirmed. It is normally cleared exclusively by the kidneys. It passes freely through the glomerular membrane, and up to 99.9% is then reabsorbed by the proximal tubules. Once reabsorbed by the proximal tubules, it degrades into amino acids.
Serum β2-M is increased in many conditions that are characterized by high cell turnover and/or immune activation. Elevated serum levels of β2-M occur in renal diseases such as glomerulopathies, tubulopathies, renal failure, and amyloidosis due to decreased rate of clearance. In kidney transplant patients, serial levels of Beta-2 Microglobulin in serum and urine are used to evaluate transplant viability and anticipate rejection. Following a successful graft, serum β2-M levels decline toward normal. An increase in these levels can be monitored to identify early signs of transplant rejection.
In addition, it has been reported that increased serum levels are found in HIV and CMV infections, rheumatoid arthritis, and autoimmune diseases. It is prognostic in multiple myeloma where low levels imply better prognosis. Elevated serum concentrations in the presence of a normal glomerular filtration rate suggest increased B2M production or release. In inflammatory disorders and in lymphoproliferative diseases, serum B2M levels are frequently elevated reflecting an increased rate of synthesis.
- As an aid in diagnosis of renal diseases such as glomerulopathies, tubulopathies
- As an aid to diagnose amyloidosis
- As an aid to diagnose some autoimmune diseases that are manifested with amyloid deposition
- As an aid in diagnosis of kidney graft rejection
- Evaluation of lymphoid malignancies
- Prognostic marker in multiple myeloma
- As an aid in diagnosis of lymphoproliferative, myeloproliferative, and myelodysplastic disorders
Increased in:
- Lymphoid malignancies, especially CLL
- Multiple myeloma, some
- Chronic renal failure (and glomerulopathies and tubulopathies)
- Lymphoproliferative disorders
- Waldenstrom's Macroglobulinemia
- Myeloproliferative/myelodysplastic disorders
- Inflammatory conditions (e.g., inflammatory bowel disease)
- Infections (e.g., HIV, CMV)
- Graft versus host disease
- Kidney allograft rejection
- Some autoimmune disorders
0.8 - 2.2 mg/L (68 - 186 nmol/L)
- Ambient - 5 days
- Refrigerated - 7 days
- Frozen - 30 days
- J Commun Dis. 2004;36:166. [PMID: 16509252]
- Clin Oncol. 2005;23;3412. [PMID: 15809451]
- Curr Opin Hematol. 2006;13:266. [PMID: 16755224]
- Semin Dial. 2006;19:105. [PMID: 16551286]
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757